|

Enhancing Survival for Patients with Pleural Mesothelioma: A Multimodal Treatment Approach

ByHolly Zink
Enhancing Survival for Elderly Patients with Pleural Mesothelioma: A Multimodal Treatment Approach

Malignant pleural mesothelioma poses a significant health challenge. Linked to asbestos exposure, this aggressive cancer demands innovative treatment strategies. Recent research provides a promising approach to combatting mesothelioma. This multimodal treatment regimen could offer hope and improved outcomes for individuals battling this disease.

A multimodal approach is when multiple treatments are used together. It is the most reliable way to improve survival in patients with malignant pleural mesothelioma.

Understanding Pleural Mesothelioma

Malignant pleural mesothelioma is an aggressive cancer. It is diagnosed late, which often presents unique challenges. While recent advancements like immunotherapy have emerged, survival rates remain low for patients. A new study focused on cytoreductive surgery combined with hyperthermic intrathoracic chemoperfusion (HITOC). This is a multimodal approach to mesothelioma treatment. By evaluating the impact of this combined therapy, researchers aim to extend disease-free survival and overall survival for patients.

The Study’s Findings

The retrospective multicenter study analyzed data from mesothelioma patients who underwent cytoreductive surgery and HITOC across four departments in Germany. The results underscored the positive impacts of this multimodal approach. They particularly showed good results for patients with epithelioid mesothelioma after achieving macroscopic complete resection.

Key findings revealed improved survival outcomes. Median survival of up to 31 months was observed, with patients receiving high-dose cisplatin showing the longest OS. Another key finding was the importance of a complete resection. The addition of chemotherapy, either neoadjuvant or adjuvant, also significantly prolonged disease-free survival. This indicats its potential in preventing tumor recurrence or progression.

Implications for Elderly Patients

Patients with mesothelioma can find hope and treatment insights in these findings. The multimodal method, combining surgery, HITOC, and chemo, offers a thorough approach.

This study shows that patients can benefit and achieve good survival rates with a multimodal approach. The treatment’s complexity doesn’t increase risks for them. As research advances, personalized treatments could further improve outcomes. These treatments would be based on individual factors and tumor biology.

Looking Ahead

The study shows that surgery and HITOC, along with chemotherapy, work well together. Ongoing research continues to improve treatment methods and provide more choices for patients. For example, the NICITA trial is looking into using chemoimmunotherapy. It aims to help epithelioid mesothelioma patients have better results.

In summary, the multimodal treatment plan suggested in the study offers hope for mesothelioma patients. Doctors can use new surgery methods and specific treatments to give patients better chances of survival and a higher quality of life.

Source:

Klotz, Laura V., Julia Zimmermann, Karolina Müller, Julia Kovács, Mohamed Hassan, Michael Koller, Severin Schmid, et al. “Multimodal Treatment of Pleural Mesothelioma with Cytoreductive Surgery and Hyperthermic Intrathoracic Chemotherapy: Impact of Additive Chemotherapy.” Cancers 16, no. 8 (January 2024): 1587. https://doi.org/10.3390/cancers16081587.

 

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    ByAlex Strauss

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    ByAlex Strauss

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    ByAlex Strauss

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    ByAlex Strauss

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    ByAlex Strauss

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • | |

    Repeat HIPEC Improves Mesothelioma Survival

    ByAlex Strauss

    If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…